Analgesic immediate and controlled release pharmaceutical composition
DCFirst Claim
Patent Images
1. A method of preparing an analgesic pharmaceutical composition for the administration of an NMDA receptor antagonist to a human or animal subject for the treatment of pain, comprising:
- providing a matrix or coated core containing an NMDA receptor antagonist to provide sustained release of a NMDA receptor antagonist;
providing a mixture containing a NMDA receptor antagonist to provide an immediate release of a NMDA receptor antagonist; and
combining the matrix or coated core with the mixture, the immediate release form and sustained release form being present in sufficient amounts to diminish or abolish wind-up.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Disclosed is a method for the therapeutic treatment of pain related to wind up in a human or animal. The method of the invention is practiced by administering to the subject an effective amount of an analgesic pharmaceutical composition which includes a NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form. The immediate release form and sustained release forn are present in sufficient amounts to diminsh or abolish wind up.
316 Citations
48 Claims
-
1. A method of preparing an analgesic pharmaceutical composition for the administration of an NMDA receptor antagonist to a human or animal subject for the treatment of pain, comprising:
-
providing a matrix or coated core containing an NMDA receptor antagonist to provide sustained release of a NMDA receptor antagonist;
providing a mixture containing a NMDA receptor antagonist to provide an immediate release of a NMDA receptor antagonist; and
combining the matrix or coated core with the mixture, the immediate release form and sustained release form being present in sufficient amounts to diminish or abolish wind-up. - View Dependent Claims (2, 3, 4, 5, 6, 42, 47)
-
- 7. A method for the therapeutic or prophylactic treatment of pain related to wind-up in a human or animal subject, the method comprising administering to the subject an effective amount of an analgesic pharmaceutical composition including an NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form, the immediate release form and sustained release form being present in sufficient amounts to diminish or abolish wind-up.
- 12. A method for the treatment of Huntington'"'"'s disease amyotrophic lateral sclerosis (ALS), AIDS-related dementia, Alzheimer'"'"'s disease, schizophrenia, motoneurone diseases and CNS and brain injuries resulting from a number of causes including trauma, stroke and neurosurgery in a human or animal subject, the method comprising administering to the subject an effective amount of an analgesic pharmaceutical composition including an NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form, the immediate release form and sustained release form being present in sufficient amounts to diminish or abolish wind-up.
-
44. A method for the therapeutic or prophylactic treatment of pain related to wind-up in a human or animal subject, the method comprising administering to the subject an effective amount of an analgesic pharmaceutical composition including an NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form, the immediate release form and sustained release form being present in sufficient amounts to diminish or abolish wind-up wherein the analgesic pharmaceutical composition comprises dextromorphan or a salt thereof in a dosage form wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer at a pH of between 1.6 and 7.2 at 37°
- C. is between 22 and 33 wt. −
% dextromorphan released after 0.5 hr, between 24 and 36 wt. −
% dextromethorphan released after 1 hour, between 28 and 42 wt. −
% dextromethorphan released after 2 hours, between 36 and 54 wt. −
% dextromethorphan released after 4 hours, between 44 and 66 wt. −
% dextromethorphan released after 6 hours, between 52 and 78 wt. −
% dextromethorphan released after 8 hours, between 68 and 100 wt. −
% dextromethorphan released after 12 hours, and greater than 80 wt. −
% dextromethorphan released after 16 hours.
- C. is between 22 and 33 wt. −
Specification